Results of the tumor set for the top differentiating genes concurred with the main MS-MLPA results in the cells set (supporting the cancer specificity of the methylated candidates), and also with previous reports describing methylation for some of the candidates under study, such as PRDM2 [32], RUNX3 [35,36], SFRP4 and SFRP5 [36], SCGB3A1 [43], DLC1 [46], CCND2 [48]. This evidence concerns the gene PRDM2 and neoplasm.